WashU Expert: Pfizer deal marks the end of U.S. ability to stop corporate tax inversion

WashU Expert: Pfizer deal marks the end of U.S. ability to stop corporate tax inversion

U.S. pharmaceutical giant Pfizer announced Nov. 23 a record-breaking $160 billion merger with Irish firm Allergan, the biggest merger to date involving the controversial strategy of tax inversion. The move marks the beginning of the end of the ability to stop corporate tax inversions under current tax rules, said Adam Rosenzweig, JD, professor of law and an expert on international tax law at Washington University in St. Louis.
WashU Expert: The role of peremptory challenge in jury selection

WashU Expert: The role of peremptory challenge in jury selection

The trial of former Oklahoma City police officer Daniel Hotlzclaw, accused of 36 charges resulting from assaults against several black women while on duty, has begun. Though African Americans make up approximately 16 percent of the population of Oklahoma County, there are no black jurors among the eight men and four women serving. The jury selection process allowed for the controversial makeup, said Peter Joy, JD, a criminal justice expert at Washington University in St. Louis.

WashU Expert: Sepper calls for robust protections against discrimination in health care

The U.S. Department of Health and Human Services is considering adoption of anti-discrimination regulations that would apply to all health care providers and build upon the Affordable Care Act mandate prohibiting discrimination “on the basis of race, color, national origin, sex, age or disability.” These new rules would help reduce disparities in the health care system, said Elizabeth Sepper, JD, associate professor of law.
View More Stories